Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2018, Vol. 45 Issue (5): 735-740    DOI: 10.12891/ceog4328.2018
Original Research Previous articles | Next articles
Efficacy and effects of transdermal hormone therapy in postmenopausal women
L.E. Prado Correia1, *(), B.C. de Almeida2, E. Chada Baracat2, I. Silva1, J.M. Soares Júnior2, C.E. Bonduki1, M. Abi Haidar1
1 Section, Department of Obstetrics and Gynecology - Federal University of São Paulo – UNIFESP/EPM, Vila Clementino, São Paulo, Brazil
2 Laboratory of Molecular and Structural Gynecology, Hospital das Clínicas, University of São Paulo Faculty of Medicine - FMUSP, Cerqueira Cesar, São Paulo, Brazil
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
The authors aimed to evaluate the influence of transdermal hormone therapy (HT) in the blood coagulation parameters. Fifty-eight postmenopausal women received: G1-transdermal estradiol (E2) (50 mg), G2-E2+oral micronized progesterone (100 mg/day), and G3- E2+oral medroxyprogesterone acetate (2.5 mg/day) for six months. Statistical relevance was seen mainly in G1 and G2. G1 showed a decrease in prothrombin time (PT), fibrinogen (FG), and thrombin time (TT) at six months (p < 0.05) compared to baseline values. G2 showed an increase of PT (p < 0.05) and a reduction of activated partial thromboplastin time (aPTT), AT III at three months (p < 0.01). AT III showed an increase after six months (p < 0.05), as well as F1+2 (p < 0.05). G3 exhibited a decrease of PT after three and six months of transdermal HT. Data suggests that E2 alone or E2+OMP are correlated with some variations of anticoagulant and procoagulant factors. E2+MPA avoids any major activation of blood coagulation in patients who receive transdermal HT.
Key words:  Transdermal hormone therapy      Postmenopausal women      17-beta-estradiol      Oral micronized progesterone      Medroxyprogesterone acetate     
Published:  10 October 2018     
*Corresponding Author(s):  L.E. PRADO CORREIA     E-mail:  luispradocorreia@gmail.com

Cite this article: 

L.E. Prado Correia, B.C. de Almeida, E. Chada Baracat, I. Silva, J.M. Soares Júnior, C.E. Bonduki, M. Abi Haidar. Efficacy and effects of transdermal hormone therapy in postmenopausal women. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 735-740.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4328.2018     OR     https://ceog.imrpress.com/EN/Y2018/V45/I5/735

[1] T.-H. Kim, E. S. Lee, H.-H. Lee, J.-M. Kim, Y.-S. Kim, B. Lee. Vaginal health: insights, views, and attitudes (VIVA). Results from a survey in South Korea[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 938-942.
[2] Y. Zheng, G. Niu, H. Zhang, W. Lu, Z. Liu. Estrogen replacement therapy is not a recommended therapy for postmenopausal women with coronary heart disease: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 219-226.
[3] O.B. Poli-Neto, P.S. Silva, T. Mangetti Gonçalvez, M.M. Máximo, J.C. Rosa-e-Silva, F.J. Candido-dos-Reis, A.A. Nogueira. Hormone therapy is not associated to pain thresholds in healthy postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 66-71.
[4] H. Zhou, W. Chen, X. Zhang, L. Wang. A case report of postmenopausal leiomyomatosis peritonealis disseminata[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 953-955.
No Suggested Reading articles found!